RS 17053 hydrochloride
(Synonyms: RS-17053) 目录号 : GC17070
An α1A-adrenergic receptor antagonist
Cas No.:169505-93-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | Rats[2]Adult male rats (n=56 to 8 per group) are pretreated (IP) with either 0, 0.1, 0.5, 2.5, or 10.0 mg/kg RS 17053 hydrochloride or with 2.0 mg/kg of the prototypical α1-Adrenoceptor antagonist prazosin. Five minutes later, each rat was treated (IP) with either 0, 5, 10 or 15 mg/kg PPA. Food and water intakes are recorded for a 30 min period starting 10 min after the treatment injection. Rats pretreated with vehicle and then treated with PPA exhibite a dose-dependent suppression of feeding with a maximal effect evident at the 15 mg/kg dose of PPA. Pretreatment with 2.0 mg/kg prazosin reverses the anorexic activity of PPA[2]. |
References: [1]. Ford AP, et al. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol Pharmacol. 1996 Feb;49(2):209-15. | |
RS 17053 hydrochloride is a novel and selective α1A-adrenoceptor antagonist [1].
α1A-adrenoceptor are widely distributed and activated either by epinephrine released from the adrenal medulla or by norepinephrine released from sympathetic nerve terminals. α1A-adrenoceptor mediate a variety of functions, including cardiac stimulation, contraction of smooth muscle, activation of hepatic gluconeogenesis， glycogenolysis, cellular proliferation and apoptosis.
In rat several tissues, RS-17053 had high affinity for the α1A -adrenoceptor and a 30 ~100-fold selectivity over the α1B - and the α1D -adrenoceptor subtypes [1]. RS 17053 had over 100-fold lower affinity for the α1A -adrenoceptor mediating contraction of the rat portal vein (pKB 7.1) and human prostate (pKB 7.1) compared with its affinity for the α1A -adrenoceptor in the rat epididymal vas deferens or the expressed α1A -clone. Therefore, RS 17053 may distinguish between subtypes of the α1A -adrenoceptor in the rat portal vein and human prostate compared with those in the rat epididymal vas deferens or the expressed α1A -clones [2].
References:
[1]. Ford AP, Arredondo NF, Blue DR Jr, et al. RS 17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-α,α-dimethyl-1H-indole-3-ethanamine hydrochloride, a selective α1A-adrenoceptor antagonist, displays low affinity for functional α1-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol Pharmacol, 1996, 49(2): 209-215.
[2]. Marshall I, Burt RP, Green GM, et al. Different subtypes of α1A-adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17053. Br J Pharmaco, 1996, 119(2): 407-415.
| Cas No. | 169505-93-5 | SDF | |
| 别名 | RS-17053 | ||
| 化学名 | 1-(5-chloro-1H-indol-3-yl)-N-(2-(2-(cyclopropylmethoxy)phenoxy)ethyl)-2-methylpropan-2-amine hydrochloride | ||
| Canonical SMILES | CC(CC1=CNC2=C1C=C(Cl)C=C2)(NCCOC3=CC=CC=C3OCC4CC4)C.Cl | ||
| 分子式 | C24H29N2O2Cl.HCl | 分子量 | 449.42 |
| 溶解度 | <22.47mg/ml in DMSO | 储存条件 | Store at RT |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2251 mL | 11.1255 mL | 22.2509 mL |
| 5 mM | 0.445 mL | 2.2251 mL | 4.4502 mL |
| 10 mM | 0.2225 mL | 1.1125 mL | 2.2251 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。